We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The poster "Cost-Effectiveness Markov Model Comparing High- and Low-Energy Transurethral Microwave Therapy for Benign Prostatic Hyperplasia" will be presented Tuesday morning, May 20th, by Dr...
Third quarter revenue totaled $3.4 million Cash balance of $816,000 as of March 31, 2014 Annualized expenses reduced by over $4.0 million since January 1, 2014 MINNEAPOLIS, May 6...
MINNEAPOLIS, April 30, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present fiscal year 2014 third quarter results on Tuesday, May 6, 2014 at 4:00...
Third quarter revenue totaled $3.4 million Cash balance of $816 thousand as of March 31, 2014 MINNEAPOLIS, April 10, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc...
MINNEAPOLIS, July 1, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office BPH therapy, announces the restructuring of payment obligations to Medtronic related...
Fri, Jun 07, 2013 12:00 - Urologix, Inc. (ULGX: OTC Link) - Venue Change - The symbol, ULGX, no longer trades on Nasdaq. As of Fri, Jun 07, 2013, ULGX trades on OTC Link. You may find a complete...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 9.9E-5 | 9900 | 1.0E-6 | 0.0001 | 1.0E-6 | 835 | 3.183E-5 | CS |
4 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 718 | 6.033E-5 | CS |
12 | 9.9E-5 | 9900 | 1.0E-6 | 0.0001 | 1.0E-6 | 1124 | 2.264E-5 | CS |
26 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 970 | 1.696E-5 | CS |
52 | 9.9E-5 | 9900 | 1.0E-6 | 0.0001 | 1.0E-6 | 4140 | 7.878E-5 | CS |
156 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 11061 | 0.00010568 | CS |
260 | -0.0046 | -97.8723404255 | 0.0047 | 0.0243 | 1.0E-6 | 63154 | 0.00706032 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions